ACVR1B

(redirected from ALK4)

ACVR1B

A gene on chromosome 12q13 that encodes activin receptor type IB, a receptor that forms a complex with other type-I and two type-II  transmembrane serine/threonine kinase receptors for activin, a dimeric growth and differentiating factor belonging to the TGF-beta superfamily of structurally related signalling proteins. Type-II receptors phosphorylate and activate type-I receptors, which autophosphorylate, then bind and activate SMAD transcriptional regulators, playing roles in cell differentiation, growth arrest and apoptosis. 

Molecular pathology
ACVR1B mutations are associated with pituitary tumours.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.
SB431542 is a selective and potent inhibitor of the TGF-[beta] pathway through suppression of the activin A receptors ALK5, ALK4, and ALK7.
Callahan et al., "SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7," Molecular Pharmacology, vol.
Callahan et al., "SB-431542 is a potent and specific inhibitor of transforming growth factor-[beta] superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7," Molecular Pharmacology, vol.
Vale, "Identification of a functional binding site for activin on the type I receptor ALK4," Journal of Biological Chemistry, vol.
Activin and MSTN association with ActRIIB leads to the recruitment, phosphorylation, and activation of the activin type I receptor, activin receptor-like kinase 4 (ALK4).
miR-221, miR-222, and miR-24 inhibit normal erythropoiesis and miR-24 targets ALK4. cMyb and miR-15a are involved in the transition from BFU-E to CFU-E stage [61-63].
ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma.
SB431542 blocks SMAD2/3 phosphorylation and nuclear translocation by inhibiting the activation of the transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 [34].
Treatment with SB431542, an inhibitor of Alk4, 5, and 7, PDGF, bFGF, oncostatin, and IGF was able to induce these Pax3(+) myogenic precursor cells into around 50-60% of MyoD(+) myoblasts in an additional 8 days.
ActA binds to type II receptor, ACVR2A or ACVR2B, leading to oligomerization, which recruits and phosphorylates the activin type I receptor-like kinase 4 (ALK4, or also known as ACVR1B) (reviewed in [26]).
The specific inhibition of the activin and nodal receptors, Alk4 and Alk7, and the TGF[beta] receptor, Alk5, avoids Smad2/Smad3 phosphorylation and the subsequent initiation of downstream signalling [90].